Reported Earnings • Apr 06
Full year 2025 earnings released: EPS: NT$2.43 (vs NT$3.20 in FY 2024) Full year 2025 results: EPS: NT$2.43 (down from NT$3.20 in FY 2024). Revenue: NT$293.2m (up 2.4% from FY 2024). Net income: NT$111.9m (down 24% from FY 2024). Profit margin: 38% (down from 51% in FY 2024). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to NT$58.90, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 34x in the Life Sciences industry in Asia. Total loss to shareholders of 29% over the past year. Announcement • Mar 13
HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026 HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city Taiwan Reported Earnings • Dec 30
Third quarter 2025 earnings released: EPS: NT$0.29 (vs NT$0.76 in 3Q 2024) Third quarter 2025 results: EPS: NT$0.29 (down from NT$0.76 in 3Q 2024). Revenue: NT$56.6m (down 26% from 3Q 2024). Net income: NT$13.6m (down 61% from 3Q 2024). Profit margin: 24% (down from 46% in 3Q 2024). The decrease in margin was primarily driven by lower revenue. Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to NT$66.00, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 21x in the Life Sciences industry in Taiwan. Total loss to shareholders of 13% over the past year. New Risk • Aug 12
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$2.98b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Market cap is less than US$100m (NT$2.98b market cap, or US$99.2m). New Risk • Apr 07
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.28b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (NT$3.28b market cap, or US$99.1m). Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to NT$70.00, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 26x in the Life Sciences industry in Taiwan. Total returns to shareholders of 19% over the past year. Reported Earnings • Apr 02
Full year 2024 earnings released: EPS: NT$3.20 (vs NT$0.74 in FY 2023) Full year 2024 results: EPS: NT$3.20 (up from NT$0.74 in FY 2023). Revenue: NT$286.4m (up 119% from FY 2023). Net income: NT$147.2m (up 340% from FY 2023). Profit margin: 51% (up from 26% in FY 2023). The increase in margin was driven by higher revenue. Announcement • Mar 19
HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 03, 2025 HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 03, 2025, at 09:30 Taipei Standard Time. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city Taiwan New Risk • Mar 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.2% average weekly change). Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to NT$89.50, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 29x in the Life Sciences industry in Taiwan. Total returns to shareholders of 60% over the past year. New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Valuation Update With 7 Day Price Move • Dec 30
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to NT$65.20, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 36x in the Life Sciences industry in Asia. Negligible returns to shareholders over past year. New Risk • Nov 11
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.8m). Announcement • Mar 29
HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 12, 2024 HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 12, 2024. New Risk • Nov 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.14b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (NT$3.14b market cap, or US$98.7m). 
